Skip to content

Placebo Effects on Blood Pressure

Physiological Effects of Placebo Interventions to Increase or Decrease Blood Pressure

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00570271
Enrollment
90
Registered
2007-12-10
Start date
2007-04-30
Completion date
2008-02-29
Last updated
2007-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Blood Pressure

Keywords

placebo effect, blood pressure, autonomic nervous system, prestige, basic research on physiological placebo effects

Brief summary

A relevant reduction of blood pressure (BP) in placebo-treated control groups is a phenomenon often observed in pharmacological studies of hypertension. This effect was shown to differ from spontaneous remission tendencies and regression to the mean effect by comparing placebo groups with untreated controls. However, it is not fully understood whether these effects are due to a global reaction of the autonomous nervous system (affecting the overall organ systems of the body) or a specific reaction (affecting the cardiovascular system only). We therefore aim to differentiate specific effects (reduction of blood pressure) from global effects (e.g. changes in electrodermal and gastric activity). In our study we aim to test the following hypotheses: 1. Placebo administration leads to a significant changes of blood pressure compared with untreated controls. 2. The direction of blood pressure change depends on the type of suggestion (either decrease or increase) 3. This effect is specific for blood pressure; changes in electrodermal and gastric activity do not differ between groups. 4. The placebo response can be enhanced by a prestige intervention (information about the suggested drug action given by doctor or in written form).

Interventions

OTHERPlacebo with BP dec (written form)

Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.

OTHERPlacebo with BP dec (doctor)

Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.

OTHERPlacebo with BP inc (written)

Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.

OTHERPlacebo with BP inc (doctor)

Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.

OTHERPlacebo info given (written)

Subject informed about receiving placebo. Information provided to subjects in written form.

OTHERPlacebo info given (doc)

Subject informed about receiving placebo. Information provided to subjects by doctor.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Informed consent

Exclusion criteria

* Not meeting inclusion criteria * Untreated hypertension (BP \> 140/90) or hypotension(BP \< 100/60) * Severe systemic disorders (tumors, tbc, diabetes, asthma etc) * Diseases with influence on cardiovascular or gastrointestinal system * Pregnancy and lactation phase * Body mass index \> 30 * Regular intake of drugs with influence on the autonomic nervous system * Insufficient compliance * Simultaneous participation in another trial

Design outcomes

Primary

MeasureTime frame
Mean arterial pressure60 minutes

Secondary

MeasureTime frame
Heart rate60 minutes
skin conductance level60 minutes
gastric activity60 minutes

Countries

Germany

Contacts

Primary ContactFrank Zimmermann-Viehoff, MD
frank.zimmermann@charite.de+49-30-84454046

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026